# Jazz Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jazz-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Dublin, Ireland
- Website: www.jazzpharma.com
- Total disclosed funding: $65M
- Latest round: Series B (Apr 16, 2004)
- Investors on record: 12

## About

Jazz Pharmaceuticals, Inc. is a global biopharmaceutical company specializing in the development of innovative therapies that address critical medical needs, particularly in oncology and sleep medicine.Founded in 2003 in Dublin, Ireland, Jazz Pharmaceuticals, Inc. focuses on creating and delivering biopharmaceutical products. The company underwent significant changes, including a Trade Sale in 2012, where it raised USD 95.00 mn from Meda AB. It has executed six deals since its inception, with the most recent deal occurring on May 31, 2007. Bruce Cozadd serves as CEO of the company.Jazz Pharmaceuticals develops and delivers a range of biopharmaceutical products designed to meet unmet medical needs, especially in oncology and sleep medicine. Key products include Zepzelca® (lurbinectedin) for extensive-stage small cell lung cancer and Xyrem® (sodium oxybate) for narcolepsy, aimed at improving the quality of life for patients in different global markets, including the United States and Europe.In the most recent fiscal year of 2023, Jazz Pharmaceuticals reported revenue of USD 3,834.20 mn and an EBITDA of USD 1,217.28 mn, primarily driven by the sales of its pharmaceutical products through healthcare providers and specialty pharmacies.Jazz Pharmaceuticals is focused on expanding its product offerings, particularly in oncology and sleep medicine, with potential new therapies currently in development. The company aims to enter new geographic markets, specifically targeting regions in Asia by 2025. The recent funding from the Trade Sale will support these initiatives, enhancing their R&D capabilities for future product launches.

## Funding rounds

- Series B, Apr 16, 2004, $50M — Adams Street Partners, KKR, Prospect Venture Partners, Versant Ventures, Thoma Bravo, Beecken Petty O'Keefe & Company, Waud Capital Partners, EGS Healthcare Capital Partners, Jasper Ridge Partners, Lehman Brothers, Oak Hill Venture Partners, Golden Gate Capital
- Series A, Apr 1, 2003, $15M — Prospect Venture Partners, Versant Ventures

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series B
- KKR (https://capitalatlas.ai/funds/kkr) — Series B
- Thoma Bravo (https://capitalatlas.ai/funds/thoma-bravo) — Series B
- Beecken Petty O'Keefe & Company — Series B
- Waud Capital Partners (https://capitalatlas.ai/funds/waud-capital-partners) — Series B
- EGS Healthcare Capital Partners (https://capitalatlas.ai/funds/egs-healthcare-capital-partners) — Series B
- Jasper Ridge Partners (https://capitalatlas.ai/funds/jasper-ridge-partners) — Series B
- Lehman Brothers (https://capitalatlas.ai/funds/lehman-brothers) — Series B
- Oak Hill Venture Partners — Series B
- Golden Gate Capital (https://capitalatlas.ai/funds/golden-gate-capital) — Series B